Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462894 | 0.84 | EGFR (0.62) | EGFR | |
| SCHEMBL5462096 | 0.82 | EGFR (0.51) | EGFRERBB2RETERBB4HDAC3 | |
| SCHEMBL5465521 | 0.82 | EGFR (0.71) | EGFRERBB2RETERBB4HDAC3 | |
| SCHEMBL5469496 | 0.81 | EGFR (0.65) | EGFRERBB2RETERBB4HDAC3 | |
| SCHEMBL4740837 | 0.81 | EGFR (0.74) | EGFRERBB2RETERBB4HDAC3 | |
| SCHEMBL16375982 | 0.80 | EGFR (1.00) | EGFRERBB2RETERBB4HDAC3 | |
| SCHEMBL5462878 | 0.80 | EGFR (0.58) | EGFRERBB2RETERBB4HDAC3 | |
| SCHEMBL5464067 | 0.80 | EGFR (0.68) | EGFRERBB2RETERBB4HDAC3 | |
| SCHEMBL5465513 | 0.80 | EGFR (0.60) | EGFRERBB2RETERBB4HDAC3 | |
| SCHEMBL5466827 | 0.80 | EGFR (0.59) | EGFRERBB2RETERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | EGFR 4385/4885ERBB2 4281/4885RET 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.